New drug duo aims to wipe out lingering cancer cells in advanced myeloma
NCT ID NCT06822972
Summary
This study is testing whether adding the drug selinexor to a newer type of immunotherapy (called a bispecific antibody) is safe and more effective for people with multiple myeloma that has come back or stopped responding to other treatments. It will enroll 27 patients who have already tried at least four prior therapies. The main goal is to see if this combination can drive the cancer down to undetectable levels and keep it away longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Health System
RECRUITINGDurham, North Carolina, 27705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.